Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPELHUS: Iptacopan (LNP023) monotherapy in complement inhibitor–naïve adult aHUS
jRCT2031210324Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2022
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of Iptacopan in atypical hemolytic uremic syndrome (aHUS), sponsored by Novartis. Primary endpoint: Complete TMA response rate at 26 weeks. Started Feb 2022; status: active, not recruiting.
02
Drugs
Iptacopan
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on jRCT2031210324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210324.